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Abstract
Introduction: The coexistence of thyroid nodules and autoimmune thyroid disease (ATD) has been widely reported. The aim of our study
was to retrospectively evaluate the prevalence and sonographic features of malignancy of thyroid nodules in ATD patients.
Material and methods: We retrospectively analysed data from 500 patients with ATD in our hospital. We recorded ultrasonographic,
histopathological and laboratory features of these patients. Thyroid ultrasonography was performed on all the patients, as well as fine
needle aspiration biopsy (FNAB) of the thyroid nodule, when required. Patients underwent operations depending on the result of the
FNAB.
Results: Of the 500 with ATD (400 female and 100 male; mean age = 42.4 years), 300 (60%) had Hashimoto’s thyroiditis (HT) and 200 (40%)
presented with Graves’ disease (GD). The frequency of thyroid nodules was statistically significantly higher in those with GD (37.8%) than
in those with HT (24.3%) (p < 0.001). One hundred and forty-nine nodules underwent FNAB (37.8%, 76 out of 200 had GD and 24.3%;
73 out of 300 had HT). The results of the cytological examination were: non-diagnostic cytology, benign, malignant and indeterminate in
19.4%, 73.8%, 2% and 4.5% of the nodules, respectively. When 55 GD and 32 HT patients, on whom total thyroidectomy had been carried
out, were evaluated, the incidence of thyroid carcinoma was similar between patients with GD (n = 3, 5.5%) and HT (n = 2, 6.3%)
(p > 0.05).
Conclusions: We observed that the prevalence of thyroid nodules in patients with GD was higher than patients with HT. However,
in general, the characteristics of the nodules and FNAB results were similar in both ATDs.
(Pol J Endocrinol 2010; 61 (6): 658–664)
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Streszczenie
Wstęp: W licznych doniesieniach stwierdza się współwystępowanie guzków tarczycy i autoimmunologicznych chorób tarczycy. Celem
pracy była retrospektywna ocena występowania i sonograficznych cech złośliwości guzków tarczycy u pajcentów z autoimmunologicz-
nymi chorobami tarczycy (ATD, autoimmune thyroid disease).
Materiał i metody: Analizie retrospektywnej poddano dane 500 pacjentów z ATD, u których przeprowadzono badania ultrasonograficz-
ne, histopatologiczne i laboratoryjne. U wszystkich pacjentów wykonano badanie ultrasonograficzne oraz, w zależności od wymagań,
biopsję aspiracyjną cienkoigłową (BAC). Pacjentów poddano operacji w zależności od wyniku BAC.
Wyniki: Spośród 500 pacjentów z ATD (400 kobiet i 100 mężczyzn, średnia wieku: 42,4 lat), u 300 (60%) stwierdzono zapalenie tarczycy
Hashimoto (HT, Hashimoto thyroids), a u 200 (40%) chorobę Gravesa (GD, Graves disease). U pacjentów z GD stwierdzono statystycznie
wyższą częstość występowania guzków tarczycy (37%) w porównaniu z pacjentami z HT (24,3%) (p < 0,001). Wykonano BAC 149 guz-
ków, w 37,8% (76 z 200) przypadków z GD i w 24,3% ( 73 z 300) z HT. Wyniki badania cytologicznego: cytologia niediagnostyczna (19,4%),
guzki łagodne (73,8%), guzki złośliwe (2%) i guzki o pośredniej złośliwości (4,5%). Spośród 55 pacjentów z GD i 32 z HT, u których
wykonano tyroidektomię totalną, stwierdzono podobną częstość występowania raka tarczycy — u pacjentów z GD (n = 3, 5,5%), a u pacjen-
tów z HT (n = 2, 6,3%) (p > 0,05).
Wnioski: Zaobserwowano wyższą częstość występowania guzków tarczycy u pacjentów z GD w porównaniu z pacjentami z HT. Nato-
miast charakterystyka guzków i wyniki BAC nie różniły sie w obu typach ATD. (Endokrynol Pol 2010; 61 (6): 658–664)
Słowa kluczowe: guzki tarczycy, zapalenie tarczycy Hashimoto, choroba Gravesa
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Introduction
The autoimmune thyroid diseases Hashimoto’s thy-
roiditis (HT) and Graves’ disease (GD) are the most com-
mon organ-specific autoimmune diseases. Hashimoto’s
thyroiditis occurs as a result of autoimmune inflamma-
tion of the thyroid gland. It has a chronic course and is
usually associated with hypothyroidism. In physical
examination, moderate enlargement of the thyroid
gland and, in many cases, the clinical features of hy-
pothyroidism, are observed. Anti-thyroglobulin anti-
bodies (Tg-Ab) and anti-thyroid peroxidase autoanti-
bodies (TPO-Ab) are positive [1]. Nodular goitre is re-
ported in 14–42% of cases [2, 3]. The rate of papillary
thyroid cancer in patients with HT is reported to be high-
er than among the general population [4–9]. The etio-
logical relation between papillary thyroid cancer and
HT is still controversial. Whether thyroiditis is induced
by neoplasm, or whether thyroiditis promotes devel-
opment of thyroid cancer, is still unclear. Although, in
some articles, cancer development on the basis of thy-
roiditis is reported to be high, it is generally believed
that lymphocytic thyroiditis is not a pre-malignant le-
sion [7, 10, 11].
The characteristics of GD are hyperthyroidism, goi-
tre, ophthalmopathy and dermatopathy. These features
can be seen in several combinations and in different fre-
quencies. In GD, the thyroid nodule is common and it
carries a risk for thyroid cancer. In some studies, thyroid
cancer accompanying GD is shown to have a more ag-
gressive course than the carcinoma occurring in patients
with non-immune hyperthyroidism and euthyroidism;
however, its pathogenesis is not well described [12, 13].
In Western countries, the prevalence of thyroid nod-
ules ranges between 4 and 7% although this rate is up
to 50% in autopsies and most nodules have a benign
nature. In studies, between 1% and 7.3% of nodules have
been found to be malignant [14–17].
We have found no study in the literature that pre-
sents the nodule frequencies in patients with autoim-
mune thyroid diseases and compares the features of
these nodules in HT and GD. Therefore, we aimed to
compare the frequency of thyroid nodules in both au-
toimmune diseases (HT and GD) and the ultrasono-
graphic features of the thyroid nodules accompanying
these diseases.
Material and methods
Study design and patients
Data in relation to 300 HT and 200 GD patients admit-
ted to the thyroid polyclinic at Ankara Numune Re-
search and Training Hospital, Division of Endocrinolo-
gy and Metabolism, between December 2005 and May
2009 was evaluated retrospectively. Diagnosis of GD
was performed on the basis of diffuse goitre accompa-
nying thyrotoxicosis signs and symptoms, elevated ra-
dioactive iodine thyroid uptake (RAIU), elevated cir-
culating anti-TSH receptor autoantibodies (TRAb) and
the presence of biochemical hyperthyroidism. To dif-
ferentiate between patients with toxic multinodular
goitre and toxic adenoma, RAIU and thyroid scintigra-
phy were performed after detailed thyroid ultrasonog-
raphy (US). Patients were diagnosed as HT if they had
TPO-Ab or Tg-Ab positivity along with clinical or sub-
clinical hypothyroidism. Other than that, heteroge-
neous parenchymal appearance, which was consistent
with thyroiditis in terms of ultrasonographic aspects,
was taken into account and patients who had not had
L-thyroxin therapy were included in the study.
The histopathological results of 55 GD and 32 HT
patients, on whom total thyroidectomy had been car-
ried out, were included in our study.
Indications for surgery were: preference of patient,
compressive symptoms, severe ophthalmopathy, pa-
tients whose US revealed features that needed investi-
gation, large goitre, failure, and/or serious side effects
of antithyroid drugs including agranulocytosis and
hepatotoxicity.
Ultrasonography
Ultrasonographic examinations of the patients were
performed in our clinic by an endocrinologist, using the
LOGIQ 3 (General Electric Healthcare, Waukesha, Wis-
consin, USA) US equipment and an 11 MHz linear
probe.
The sizes of the thyroid lobes as well as characteris-
tics of thyroid parenchyma and nodules were noted.
Ultrasonography-guided biopsy (fine needle aspiration
biopsy, or FNAB) was used for nodules greater than
1 cm in diameter and for nodules < 1 cm with suspi-
cious US findings (e.g. a hypoechogenic nodule in as-
sociation with punctuated calcification and/or intran-
odular vascularity and/or irregular borders).
The results of the cytology were categorised as non-
diagnostic (ND), benign, malignant or indeterminate.
A second biopsy was performed if the FNAB result was
ND-FNAB. Total thyroidectomy was performed on the
patients whose FNAB result was malignant, indetermi-
nate or ND-FNAB twice.
Laboratory assays
Serum thyroid-stimulating hormone (TSH), free tri-
iodothyronine (fT3), free thyroxine (fT4), TRAb, TPO-
Ab and Tg-Ab levels were assayed. Serum TSH, fT3 and
fT4 levels were evaluated using the Abbott Architect
2000 device and Chemiluminescence Microparticle
Immunoassay (CMIA) method. Serum Tg-Ab (normal
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range < 50 IU/mL) and TPO-Ab (normal range < 10 IU/
/mL) values were evaluated through immunoradiometric
assay (IRMA) methods (ICN Pharmaceuticals, USA). Anti-
TSH receptor antibodies in patients were measured using
a radioreceptor assay (Radim, Italy). The normal range for
TRAb in our laboratory was found to be < 9 U/L (9–14 U/L
borderline, > 14 U/L positive). TSH levels lower than
0.34 µIU/mL were accepted as hyperthyroidism and TSH
levels over 5.60 µIU/mL were accepted as hypothyroidism.
Statistical analysis
Data analysis was performed using Statistical Package
for Social Sciences (SPSS) version 13.0 software (SPSS
Inc., Chicago, Illinois, USA). Metric discrete variables
were shown as mean ± standard deviation, and per-
centages were used for categorical variables. Chi-square
tests were used to assess the statistical significance of
differences between groups in the frequency distribu-
tion of categorical variables. Medians were compared
using the Mann Whitney U test when the number of
independent groups was two. Differences between the
medians of more than two groups were evaluated us-
ing the Kruskal Wallis test. A p value less than 0.05 was
considered to be statistically significant.
Results
Three hundred out of 500 patients with ATD had HT
and 200 had GD. Of the 300 patients with HT, 90% (270)
were female and the mean age was 40 (20–65 years)
while 65% (130) of 200 GH patients were female and
the mean age was 44 (22–68 years). The mean thyroid
volume of the GD patients was statistically significantly
higher than that in the patients with HT [14.01 ± 13.0 cm3
in HT; 26.3 ± 18.5 cm3 in GD (p < 0.001)].
Thyrotropin level in patients with HT was 13.0 ±
± 23.9 µIU/mL, while it was 0.2 ± 0.6 µIU/mL in pa-
tients with GD. Free T3 level was 2.5 ± 0.5 pg/mL in HT
and 7.8 ± 7.7 pg/mL in GD. Free T4 level was 0.8 ±
± 0.3 ng/dL in HT and 2.0 ± 1.2 ng/dL in GD (p < 0.001
for all) (Table I).
A thyroid nodule was found in 24.3% of the 300 pa-
tients with HT (n = 73) and in 37.8% of the 200 patients
with GD (n = 76). The frequency of thyroid nodules
was statistically significantly higher in GD (p < 0.001).
Thyroid nodule number was statistically significantly
higher in GD (p < 0.001) (Table I).
Thyroid cancer was observed in 0.6% of patients
with HT (n = 2), and in 1.5% of GD patients (n = 3).
However, there was no statistically significant differ-
ence regarding thyroid cancer frequency between HT
and GD (p > 0.05). Besides, given the cases on which
total thyroidectomy was carried out, the incidence of
thyroid carcinoma was similar between patients with
GD (3 out of 55, 5.5%), and patients with HT (2 out of
32, 6.3%) (p > 0.05).
The characteristics of the thyroid nodules in HT and
GD patients are presented in Table II. In 73 of the pa-
Table I. Characteristics of the patients with autoimmune thyroid diseases
Tabela I. Charakterystyka pacjentów z autoimmunologicznymi chorobami tarczycy
Hashimoto’s thyroiditis (n = 300) Graves’ disease (n = 200) p
Age (years) 41.4±13.3 43.9±14.3 NS
TSH [µIU/mL] 13.0±23.9 0.2±0.6  < 0.001
fT3 [pg/mL] 2.5±0.5 7.8±7.7  < 0.001
fT4 [ng/dL] 0.8±0.3 2.0±1.2  < 0.001
TPO-Ab [IU/L] 315.5±451.2 206.7±262.1 0.004
Tg-Ab [IU/L] 431.7±775.8 326.6±736.2 NS
Presence of thyroid nodule (%) 73 (24.3) 76 (37.8)  < 0.001
Number of thyroid nodules 0.2±0.5 (0–3) 0.5±0.9 (0–5)  < 0.001
Mean nodule volume [cm3] 0.33 (0.01–2.81) 1.77 (0.01–49.9) NS
Thyroid volume [cm3] 14.01±13.0 26.3±18.5  < 0.001
Tumour diameter [cm3] 0.7±0.3 0.5±0.3 NS
Rate of malignancy 2 3
In all patients (%)  0.6 1.5 NS
In nodules of patients who underwent 6.3 5.5
total thyroidectomy (%)
fT3 — free triiodothyronine; fT4 — free thyroxine; Tg-Ab — anti-thyroid thyroglobulin antibodies; TPO-Ab — anti-thyroid peroxidase autoantibodies;
TSH — thyroid-stimulating hormone; NS — not significant
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tients with nodular variant of HT, 91.8% of the thyroid
nodules were solid, 5.5% were cystic and 2.7% had both
solid and cystic components. In 76 GD patients with
thyroid nodules, 84.2% of the thyroid nodules were
solid, 13.2% were cystic and 2.6% had both solid and
cystic components. No statistically significant difference
was observed when HT and GD were compared regard-
ing the structure of the thyroid nodule (p > 0.05).
When we investigated the echogenicity of the thy-
roid nodules of 73 patients with HT, 38.4% was hypo-
echoic, 24.7% were isoechoic, 19.1% were hyperechoic
and 17.8% had a mixed echogenicity; while of 76 GD
patients, 32.9% were hypoechoic, 15.8% were isoecho-
ic, 7.9% were hyperechoic and 43.4% had a mixed
echogenicity. No statistically significant difference was
observed between the thyroid nodules of mixed echoge-
nicity in patients with GD and HT (p > 0.05).
While microcalcifications were found in 17.8% and
nodular shape irregularity was found in 4.1% of nodu-
lar patients with HT, the rates in nodular GD were 10.5%
and 2.6%, respectively. There was no statistically sig-
nificant difference between HT and GD regarding the
presence of microcalcification and shape features
(p > 0.05). Malign nodules in GD patients were hypo-
echoic and they consisted of microcalcification; a halo
was not observed in any of the patients. While shapes
were regular in two of the malign nodules, shape irreg-
ularity was existent in one of the malign nodules. Ma-
lign nodules in patients with HT showed mixed echoge-
nicity. Microcalcifications were observed in one of the
malign nodules. The shapes of both malign nodules
were regular and a halo was existent. While long axis to
short axis (LA/SA) ratio was < 1.5 in four of the malign
nodules, anteroposterior diameter to transverse diame-
ter ratio (AT) was ≥ 1 in both of the malign nodules in
the patients with GD. On the other hand, AT was ≥ 1 in
one of the malign nodules in patients with HT.
Though the number of nodules positively correlat-
ed with age, TSH level and tumour diameter showed
a positive correlation in malign patients (Table III).
In patients with GD, there was no significant differ-
ence between TRAb positive and negative individuals
regarding the number of nodules, volume of nodules,
presence of nodules and ultrasonographic features of
the nodules (Table IV).
Fine needle aspiration biopsy outcomes of the nod-
ular patients with HT were 76.3% benign, 13.6% non-
diagnostic, 6.7% indeterminate and 2.7% malignant,
while the rates in patients with nodular GD were found
to be 72.4%, 23.7%, 2.6% and 1.3%, respectively. Those
patients with inadequate FNAB for the second time in
a row were referred for surgery.
Discussion
Clinical and ultrasonographic characteristics of HT re-
flect diffuse goitre, although nodular goitre is not infre-
quently observed in these patients. Studies on HT have
reported a nodular goitre rate of 14-42% [2, 3, 18, 19].
In HT, if a nodular lesion is observed, FNAB should
be performed [20]. Rates ranging between 0.3% and 58%
have been reported on the co-existence of papillary thy-
roid cancer and HT [4–9]. This very wide range can be
attributed to ethnic and geographical features, gender,
theselection of patients referred for thyroidectomy and
differences in histopathological comments in the stud-
Table II. Selected ultrasonographic features in thyroid nodules according to autoimmune thyroid diseases
Tabela II. Wybrane cechy ultrasonograficzne guzków tarczycy w obu rodzajach ATD
Hashimoto’s thyroiditis (n = 73) Graves’ disease (n = 76) p
Structure (%)
Solid 67 (91.8) 64 (84.2)
Cystic 4 (5.5) 10 (13.2) 0.306
Mixed 2 (2.7) 2 (2.6)
Echogenity (%)
Hypoechoic 28 (38.4) 25 (32.9)
Isoechoic 18 (24.7) 12 (15.8) 0.006
Hyperechoic 14 (19.1) 6 (7.9)
Mixed 13 (17.8) 33 (43.4)
Microcalcification (%) 13 (17.8) 8 (10.5) 0.179
Shape irregularity (%) 3 (4.1) 2 (2.6) 0.708
AT ≥ 1 (%) 15 (20.5) 12 (15.8) 0.618
LA/SA < 1.5 (%) 36 (49.3) 43 (56.6) 0.527
AT — anteroposterior diameter to transverse diameter ratio; LA/SA — long axis to short axis ratio
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ies [6, 21]. Nevertheless, it is accepted that the incidence
of papillary thyroid cancer is higher in patients with
HT compared to the general population [7, 8]. In our
study, a thyroid nodule was found in 24.3% of HT pa-
tients, though thyroid cancer was observed in only 0.6%.
Besides, when the cases on which total thyroidectomy
was carried out were evaluated, it was observed that
6.3% of the cases had thyroid cancer. The fine needle
aspiration biopsy outcomes of 73 patients with the nod-
ular variant of HT were found to be benign in 76.3%,
non-diagnostic in 13.6%, indeterminate in 6.7% and
malignant in 2.7%. The incidence of thyroid cancer was
lower than in the literature on patients with HT in our
series, because the rates of thyroid cancer in previous
studies were generally obtained from the data of pa-
tients who had undergone thyroidectomy. The rate of
thyroid cancer in cases on which total thyroidectomy
was carried out, made us think that the rate of thyroid
cancer would be higher when all cases were subjected
to surgery. Our aim was not to determine the preva-
lence of thyroid cancer, but rather to compare the fre-
quency of thyroid nodules, cytology results and nod-
ule features. A study which aims to reveal the frequen-
cy of thyroid cancer in ATD patients would of course
require a method that investigates the histopathologi-
cal outcomes of the patients who had undergone total
thyroidectomy.
Long-term studies, including series with a large
number of patients, suggest that recurrence of thyroid
cancer and metastasis are observed less frequently and
the term of survival is longer in patients with HT and
this has been attributed to the lymphocytic response
that limits the growth and metastasis potential of the
tumour [6, 7, 21]. Our study found a relation between
TSH levels and the diameter of a tumour. Fiore et al.
found a direct relationship between TSH levels and the
risk of papillary thyroid carcinoma in patients with thy-
roid nodular disease [22]. In the above-stated study, no
relation was found between thyroid autoimmunity and
the risk of thyroid cancer. Similarly, Haymart et al. states
that incidence of thyroid cancer correlates with higher
TSH independently of age [23]. Besides, in this study,
Table IV. Comparison of ultrasonographic and histopathological features according to TRAb results
Tabela IV. Porównanie cech ultrasonograficznych i histopatologicznych w zależności od wyniku TRAb
TRAb+ (n = 166) TRAb– (n = 34) p
Number of thyroid nodules 0.49 (0–3) 0.24 (0–2) 0.117
Mean nodule volume [cm3] 0.45 (0.11–1.61) 1.9 (0.01–49.92) 0.666
Thyroid volume [cm3] 26.93 (1.29–141.41) 22.95 (7.69–51.11) 0.254
Malignancy (%) 2 (3.1) 1 (9.1) 1.000
Table III. Correlation coefficients and levels of significance between the level of change in terms of age, thyroid function,
autoantibodies and tumour diameter
Tabela III. Współczynniki korelacji i poziomy znamienności statystycznej różnic w zakresie wieku, czynności tarczycy,
przeciwciał i wymiarów guza
Number of nodules Tumour diameter
Rho p Rho p
Age 0.161  < 0.001 –0.532 0.357
TSH –0.098 0.029 0.968 < 0.001
fT3 0.016 0.720 –0.308 0.614
fT4 0.003 0.938 –0.130 0.835
TPO-Ab 0.010 0.837 –0.383 0.617
Tg-Ab 0.036 0.432 0.966 0.034
Number of thyroid nodules – – –0.183 0.769
Thyroid volume 0.229 < 0.001 –0.369 0.548
Tumour diameter –0.183 0.769 – –
fT3 — free triiodothyronine; fT4 — free thyroxine; Tg-Ab — anti-thyroid thyroglobulin antibodies; TPO-Ab — anti-thyroid peroxidase autoantibodies;
TSH — thyroid-stimulating hormone
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researchers have found that higher TSH is associated
with extrathyroidal extension of this disease. In GD, the
rate of thyroid nodules is almost three times higher than
in the general population and the risk of thyroid can-
cer rises in patients with nodular GD [24]. The frequen-
cy of nodules varies between 15% and 45% in GD [24–
28]. The risk of carcinoma in a thyroid nodule of GD is
higher than in other nodular thyroid disease [24]. Patho-
genesis in relation to the development of a thyroid nod-
ule in GD is unclear and the cause of the increase in the
rate of thyroid cancer is still being debated [29]. Al-
though one study found thyroid cancer to be at a rate
of 9% in patients operated for GD [30], this high inci-
dence of carcinoma has not been reproduced in other
studies. The risk of thyroid carcinoma ranges between
0% and 9.8% in GD [24]. For example, in a study per-
formed on 468 GD patients, the frequency of nodules
was 12.6%, the risk of thyroid cancer in nodules was
10% and the risk of thyroid cancer for all patients was
1.3% [29]. In one study, a thyroid nodule was found in
25% of 557 patients and thyroid cancer was found in
15% of thyroid nodules and in 3.8% of all patients [31].
In our study, 37.8% of 200 GD patients had thyroid
nodules and 1.5% had thyroid cancer. When the cases
on which total thyroidectomy had been carried out were
evaluated, it was observed that 5.5% of the cases had
thyroid cancer. The high frequency of thyroid nodules
may be attributed to iodine deficiency in our society.
Although iodine deficiency has improved since 1998,
when iodine prophylaxis was initiated, moderate to
severe iodine deficiency still exists in 27.8% of our pop-
ulation [32].
In terms of the surveys, which were performed pri-
or to (1997) the iodine prophylaxis and in its early years,
this rate was 58% and 38.9%, respectively.
In our study, similar to patients with HT, GD pa-
tients had a lower frequency of thyroid cancer compared
to the literature, because thyroidectomy was not per-
formed on all cases, since our primary aim was not to
detect the rate of cancer. Thyroid microcarcinomas are
found in 5% to 36% of adults at autopsy. Clinically de-
tectable thyroid carcinomas constitute less than 1% of
all human cancers, while the annual incidence rate in
various parts of the world ranges from 0.5 to 10 cases
per 100,000 [33]. The possibility of a bias related to the
pathological examination of the excised thyroid is sup-
ported by studies in which the incidence of carcinoma
can be compared between patients with GD who have
undergone thyroidectomy and those who have not.
A possible role of TRAb in the development and pro-
gression of thyroid cancer was suggested on the basis
of in vitro experiments and confirmed in clinical stud-
ies [26, 34–37]. At this point, we cannot make any con-
clusion on the basis of our series. We did not consider
the possible relationship between TRAb levels and the
presence of nodules in patients with GD, and found no
significant increase of TRAb levels preceding or accom-
panying the growth of nodules.
Today, like all diseases, ATDs can be diagnosed earli-
er, thanks to a wide distribution of thyroid clinics, as well
as better access to molecular and ultrasonographic ex-
aminations. Therefore, in these groups of patients, expo-
sure time to abnormal TSH levels previously blamed for
pathogenesis (high in HT and low in GD) is shorter. Sim-
ilarly, early diagnosis and removal of TRAb source by
early thyroidectomy in GD patients might result in less
thyroid gland stimulation causing malignancy.
While there are studies in which solid structure is
reported as a weak indicator of malignancy in thyroid
nodules (since most benign nodules are of solid struc-
ture) some other publications report it as a strong indi-
cator of malignancy [38–41]. In our study, 91.8% of the
nodules in HT patients, and 84.2% of the nodules in
GD patients, had solid structure. While malign nodules
in GD patients had solid structure, the nodules in HT
patients had mixed structure.
In previous studies, hypoechoic ultrasonographic
appearance in thyroid nodules was significantly asso-
ciated with malignancy [39–42]. Thyroid nodules of GD
patients had a higher rate of mixed echogenicity when
compared to those of HT patients. However, hypoechoic
pattern was found to be similar in both diseases (HT
38.4% and GD 32.9%). As mixed echogenicity did not
predict malignancy, it was suggested that there was no
significant difference between these two diseases. In
these groups of patients, ultrasonographic characteris-
tics of the benign and malign nodules could not be spec-
ified as the number of malign cases was limited. While
a hypoechoic pattern was observed in the malign nod-
ules of GD patients, mixed echogenicity was observed
in the malign nodules of HT patients.
In many studies, microcalcifications in thyroid nod-
ules have been associated with malignancy [38, 43, 44].
We detected microcalcifications in 17.8% of the nod-
ules of HT patients and 10.5% of the nodules of GD
patients. Malign nodules in Graves’ patients consisted
of microcalcifications. One of the malign nodules in HT
patients had microcalcifications.
Spherical shape was independently correlated with
the risk of malignancy. In various studies, this feature
has been evaluated on the basis of LA/SA or AT ratio.
A long to short axis ratio greater than 2.5 was 100% pre-
dictive of a benign process, although it was present in
only 4% of our cohort [45]. A long axis/short axis ratio
(LA/SA) of < 1.5 was associated with malignancy in sub-
centimeter thyroid nodules [39]. Long axis to short axis
ratio was found to be < 1.5 in 49.3% of the nodules in
HT patients and 56.6% of the nodules in GD patients.
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LA/SA ratio was < 1.5 in 4 of the malign nodules. It is
reported that an AT rate of ≥ 1.0 is a very good predic-
tor of the risk of thyroid cancer in thyroid nodules [46].
In GD patients, there is a relation between thyroid can-
cer and US features such as microcalcification, hypo-
echoic feature, shape irregularity and an A/T rate of ≥ 1
[47]. AT was found to be ≥ 1 in 20.5% of the nodules in
HT patients and 15.8% of the nodules in GD patients.
Although the rates of spherical shapes in all nodules
were similar, AT was found to be ≥ 1 in both malign
nodules in Graves’ patients. On the other hand, AT was
≥ 1 in one of the malign nodules in HT patients.
Conclusions
Our study found a higher frequency of thyroid nod-
ules in GD patients compared to HT patients. Howev-
er, mean thyroid nodule volume and cytological results
of the nodules were similar. Ultrasonographic features
of the nodules were generally similar, although mixed
echogenicity was found to be more frequent in GD pa-
tients. We have concluded that there is a need for large
scale studies, in which frequency of thyroid nodules is
compared between individuals with Graves’ disease and
Hashimoto’s thyroiditis.
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